NCT01025349View on ClinicalTrials.gov

Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Bevacizumab, docetaxel, cisplatin

"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."

Trial Locations (1)

110

Taipei Medical University Hospital, Taipei

All Listed Sponsors
lead

Taipei Medical University Hospital

OTHER

NCT01025349 - Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter